PER-074-14已完成未知
A PHASE III RANDOMIZED CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERSUS PACLITAXEL, DOCETAXEL OR VINFLUNINE IN SUBJECTS WITH RECURRENT OR PROGRESSIVE METASTATIC UROTHELIAL CANCER
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 2 人开始时间: 2015年4月28日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 100（—）
- 性别
- All
入选标准
- •Willing and able to provide written informed consent
- •≥18 years of age
- •Histologically or cytologically confirmed diagnosis of urothelial cancer of the renal pelvis, bladder, ureter or uretra
- •Progression or recurrence of urotheliar cancer following receipt of a first-line platinum containing regimen
- •Have received no more than 2 prior lines o systemic chemotherapy for urothelial cancer
- •Provided tissue for biomarker analysis
- •Measurable disease based on RECIST 1.1
- •Performance status of 0, 1 or 2 on the ECOG Performance Scale
- •Adequate organ function
- •Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication
- •Female subjects childbearing potential must be willing to use 2 methods of birth control or be surgicallly sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of pembrolizumab or 180 days after the last dose of paclitaxel, docetaxel or vinflunine
- •Male subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study pembrolizumab (MK-3475) or 180 days after the last dose of paclitaxel, docetaxel or vinflunine.
排除标准
- •Disease suitable for local therapy with curative intent
- •Participating in or has participated in a study of an investigational agent or device
- •Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy
- •Prior anti-cancer monoclonal antibody or not recovered from adverse events
- •Prior chemotherapy, targeted small molecule therapy, or radiation therapy or has not recovered from adverse events
- •Known additional malignancy that is progressing or requires active treatment
- •Known active central nervous system metastases and/or carcinomatous meningitis
- •Active autoimmune disease requiring systemic treatment or a documented history of clinically severe autoimmune disease
- •Active cardiac disease
- •Evidence of interstitial lung disease or active non-infectious pneumonitis
- •Active infection requiring systemic therapy
- •History of severe hypersensitivity reaction
- •Requires ongoing therapy with a medication that is a strong inhibitor of the CYP3A4 enzymes
- •Known psychiatric or substance abuse disorders
- •Is pregnant or breastfeeding, or expecting to conceive
- •Prior therapy with an anti-PD-1 or anti-PD-L1 agent, or with an agent directed to another co-inhibitory T-cell receptor
- •Prior chemotherapy for urothelial cancer with all available study therapies in the control arm. Known history of Human Immunodeficiency Virus. Known active Hepatitis B or C. Received a live virus vaccine within 30 days of planned start of trial treatment
研究者
相似试验
已完成
3 期
A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial CancerUrothelial Cancer10038364Bladder CancerNL-OMON44766Merck Sharp & Dohme (MSD)10
进行中（未招募）
1 期
MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancerEUCTR2014-002009-40-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.470
已完成
3 期
A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel,Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic UrothelialCancerC67C66Malignant neoplasm of bladderMalignant neoplasm of ureterDRKS00008947Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.542
进行中（未招募）
1 期
MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancerMetastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapyMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864EUCTR2014-002009-40-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.470
进行中（未招募）
1 期
MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancerMetastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapyMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864EUCTR2014-002009-40-NLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.470